Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 2/20 | 0.52 |
| ▸ | CMA1 | P23946 | 2/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249872 | 0.86 | CTSG (0.53) | CTSGCMA1SLC7A5ALDH1A1GAA | |
| SCHEMBL5746476 | 0.85 | SIRT2 (0.47) | CTSGCMA1ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL2767340 | 0.84 | CTSG (0.49) | CTSGCMA1SLC7A5ALDH1A1GAA | |
| SCHEMBL12750998 | 0.83 | CTSG (0.51) | CTSGCMA1SLC7A5ALDH1A1GAA | |
| SCHEMBL11153241 | 0.82 | ALDH1A1 (0.41) | CTSGCMA1ALDH1A1GAAEGFR | |
| SCHEMBL12400239 | 0.81 | SLC7A5 (0.68) | CTSGCMA1SLC7A5ALDH1A1GAA | |
| SCHEMBL19857172 | 0.80 | HDAC6 (0.48) | ALDH1A1HPGDCYP4F2CYP4A11CA12 | |
| SCHEMBL4137892 | 0.80 | AKR1B1 (0.50) | ALDH1A1GAAHPGDMAPTTSHR | |
| SCHEMBL184666 | 0.80 | CYP4F2 (0.56) | CTSGCMA1ALDH1A1GAAGFER | |
| SCHEMBL5051584 | 0.80 | CTSG (0.48) | CTSGCMA1SLC7A5ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634155-A1 | RBM39 SULFONAMIDE INHIBITORS | Recursion Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024129634-A1 | RBM39 SULFONAMIDE INHIBITORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024129634-A1 | RBM39 SULFONAMIDE INHIBITORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| EP-4013762-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555609-A | Macrocyclic sulfonamide derivatives useful as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3283472-B1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | UNIV INDIANA RES & TECH CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021032588-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273228-B2 | Hepatitis B viral assembly effectors | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-04-30 | — | — | US | disclosed |
| WO-2007047431-A2 | SULFONYL-SUBSTITUTED ARYL COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | KALYPSYS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1756108-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1751133-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1735280-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | Kalypsys, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060019956-A1 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-05 | — | — | US | disclosed |
| WO-2005115983-A1 | ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005105780-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005103050-A2 | AZAINDOLES USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003968-A1 | Azaindoles useful as inhibitors of rock and other protein kinases | ROCK2, ROCK1, TNK2 | CTSG 3186/4885CMA1 1388/4885SLC7A5 4028/4885 |
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | CTSG 2075/4885CMA1 3393/4885SLC7A5 2184/4885 |
| US-10273228-B2 | Hepatitis B viral assembly effectors | HAVCR2, MAVS, HCCS | CTSG 3269/4885CMA1 3430/4885SLC7A5 4494/4885 |
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | CTSG 692/4885CMA1 2388/4885SLC7A5 640/4885 |
| US-20060019956-A1 | Compositions useful as inhibitors of rock and other protein kinases | ROCK1, ROCK2, PRKCH | CTSG 1694/4885CMA1 1109/4885SLC7A5 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.